伴随诊断在嵌合抗原受体T细胞治疗中的研究进展

Progress of companion diagnostics in chimeric antigen receptor T-cell therapy

嵌合抗原受体T细胞(CAR-T)免疫治疗恶性血液肿瘤取得了较好的疗效。作为精准个体化治疗方式, CAR-T治疗逐渐向商品化发展, 除出台治疗相应政策和指导原则外, 也应跟进并完善相应的检测方案, 以实现其效应最大化和精准个体化。文章在CAR-T治疗中引入并扩展首先在靶向药中出现的"伴随诊断"概念, 介绍各类检测技术和生物标志物在CAR-T治疗全程中患者筛选、安全性监测、疗效和CAR-T功能评估方面的意义。

Chimeric antigen receptor T-cell(CAR-T)immunotherapy has achieved good efficacy in treatment of hematological malignancies.As a precise and individualized treatment method,CAR-T is gradually moving towards commercialization.In addition to the introduction of corresponding policies and guiding principles,the related detection protocols should also be updated and improved to maximize its effect and achieve precise individualization.This article introduces and expands the concept of"companion diagnostics"that first appeared in targeted drugs,and introduces the significances of various detection technologies and biomarkers for patient screening,safety monitoring and evaluation of efficacy and CAR-T function in the whole process of CAR-T treatment.